TY - JOUR
T1 - Grey zones sul diabete mellito in ambito cardiologico. Opinioni degli esperti
AU - Trevisan, Roberto
AU - Grosu, Aurelia
AU - Avogaro, Angelo
AU - Agostoni, Piergiuseppe
AU - Ceconi, Claudio
AU - Genovese, Stefano
AU - Bossi, Antonio
AU - Pitì, Antonio
AU - Senni, Michele
AU - Maggioni, Aldo Pietro
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2020/12/1
Y1 - 2020/12/1
N2 - Clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies in diabetes mellitus and cardiovascular disease. The first topic concerns the appropriateness of second level cardiovascular screening of the entire population of diabetic patients. The second gap in evidence concerns the validity of a target of glycated hemoglobin considering the last trials. The work has also been implemented with the evidences deriving from important randomized studies published after the date of the Conference.
AB - Clinical guidelines, while representing an objective reference to perform correct therapeutic choices, contain grey zones, where recommendations are not supported by solid evidence. In a conference held in Bergamo in October 2018, an attempt was made to highlight some of the main grey zones in Cardiology and, through a comparison between experts, to draw shared conclusions that can illuminate our clinical practice. This manuscript contains the statements of the symposium concerning the controversies in diabetes mellitus and cardiovascular disease. The first topic concerns the appropriateness of second level cardiovascular screening of the entire population of diabetic patients. The second gap in evidence concerns the validity of a target of glycated hemoglobin considering the last trials. The work has also been implemented with the evidences deriving from important randomized studies published after the date of the Conference.
UR - http://www.scopus.com/inward/record.url?scp=85096736553&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85096736553&partnerID=8YFLogxK
U2 - 10.1714/3472.34545
DO - 10.1714/3472.34545
M3 - Articolo
C2 - 33231210
AN - SCOPUS:85096736553
SN - 1827-6806
VL - 21
SP - 916
EP - 922
JO - Giornale Italiano di Cardiologia
JF - Giornale Italiano di Cardiologia
IS - 12
ER -